Abstract C022: Integrated molecular approach to identify biologic factors contributing to breast cancer disparities in Chicago
Authors: Danciu Oana C. , Madak-Erdogan Zeynep , Patel Hariyali , Banks Landan , Buckley Jermya , Rauscher Garth , Fareeduddin Anita , Martin Elonia , Garcia Carlos , Schulte Lauren , Taiym Deanna , Kim Julie , Gradishar William , Hegerty Scott , Bargaje Archana , Frasor Joanna , Hoskins Kent 
Published: August 2020

African American (AA) women have a 4- to 5-fold greater risk of death from hormone receptor-positive (HR +) breast cancer (BC) compared to white women, even after controlling for stage at diagnosis, treatment, and other prognostic factors. Biologic mechanisms are activated in HR + BC arising in AA women that result in a higher rate of distant metastases and/or resistance to endocrine therapies. We are performing a metabolomic analysis of serum from AA and white women with newly diagnosed BC, as well as a racially diverse, healthy control population, to identify potential oncometabolites that promote aggressive phenotypes in HR+ BC cells. The association between candidate oncometabolites and established demographic variables related to poor outcomes in AA women with BC, including neighborhood socioeconomic deprivation and individual patient and tumor characteristics, will also be explored. AA and white women, age 20-79, with a new diagnosis of stage I-III ER+ BC who have not yet initiated treatment have been recruited from 3 cancer institutions in Chicago. Control subjects (women presenting for a screening mammogram without breast symptoms and no history of cancer) have been recruited in mammography centers. Serum for metabolite profiling and demographic data were collected. By collecting serum samples prior to initiation of any treatment, the profiles generated will also reflect the metabolome of the tumor itself. Analyses will be adjusted for tumor intrinsic subtype (Luminal A, Luminal B, HER-2 enriched and basal-like) since different molecular pathways predominate in the different subtypes and metabolite profiles are expected to vary. Target enrollment is 300 subjects; to date we have enrolled 21 AA women with HR + BC and 73 AA controls, 15 white women with HR +BC and 11 white women controls. Metabolomic analysis and demographic data and neighborhood/geo-spatial analysis will be presented with the poster. We expect to identify biochemical differences in serum that are related to race and cancer status. Associations between candidate oncometabolites and key neighborhood-level and individual-level variables that are associated with BC disparities will also be generated.

Citation Format: Oana C. Danciu, Zeynep Madak-Erdogan, Hariyali Patel, Landan Banks, Jermya Buckley, Garth Rauscher, Anita Fareeduddin, Elonia Martin, Carlos Garcia, Lauren Schulte, Deanna Taiym, Julie Kim, William Gradishar, Scott Hegerty, Archana Bargaje, Joanna Frasor, Kent Hoskins. Integrated molecular approach to identify biologic factors contributing to breast cancer disparities in Chicago [abstract]. In: Proceedings of the Eleventh AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2018 Nov 2-5; New Orleans, LA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl):Abstract nr C022.